Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

WAY-470

From Wikipedia, the free encyclopedia
WAY-470
Identifiers
  • 1,16-diazatetracyclo[8.8.1.02,9.014,19]nonadeca-2(9),10,12,14(19)-tetraene
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC17H22N2
Molar mass254.377 g·mol−1
3D model (JSmol)
  • C1CCCC2=C(CC1)C3=CC=CC4=C3N2CCNC4
  • InChI=1S/C17H22N2/c1-2-4-9-16-14(7-3-1)15-8-5-6-13-12-18-10-11-19(16)17(13)15/h5-6,8,18H,1-4,7,9-12H2
  • Key:FEOKYCHGJRHIDE-UHFFFAOYSA-N

WAY-470 is a drug which acts as an agonist at 5-HT2A and 5-HT2C receptors though with lower affinity at 5-HT2B. It has similar binding affinity to 5-HT2A and 5-HT2C but shows functional selectivity for 5-HT2C.[1][2]

See also

[edit]

References

[edit]
  1. Sabb AL, Vogel RL, Welmaker GS, Sabalski JE, Coupet J, Dunlop J, et al. (May 2004). "Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor". Bioorganic & Medicinal Chemistry Letters. 14 (10): 2603–2607. doi:10.1016/j.bmcl.2004.02.100. PMID 15109661.
  2. Lee J, Jung ME, Lee J (November 2010). "5-HT2C receptor modulators: a patent survey". Expert Opinion on Therapeutic Patents. 20 (11): 1429–1455. doi:10.1517/13543776.2010.518956. PMID 20849206. S2CID 32729624.